# Xencor Inc: financial statements, quarterly

XNCR · Nasdaq · CIK 1326732 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/xncr.md) · [Financials](/companies/xncr/financials.md) · [Filings](/companies/xncr/filings.md) · [Insiders](/companies/xncr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/xncr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [59.2](/filings/0001326732-25-000021.md) | [51.0 d](/filings/0001326732-26-000015.md) | [16.0](/filings/0001326732-25-000053.md) | [23.9](/filings/0001326732-25-000075.md) | [17.8](/filings/0001326732-25-000087.md) | [52.8 d](/filings/0001326732-26-000015.md) | [32.7](/filings/0001326732-26-000043.md) | [43.6](/filings/0001326732-26-000056.md) | [21.0](/filings/0001326732-25-000087.md) | [28.2 d](/filings/0001326732-26-000015.md) | [4.5](/filings/0001326732-26-000043.md) | [51.2](/filings/0001326732-26-000056.md) |
| Research and development | $m | [64.9](/filings/0001326732-25-000021.md) | [63.0 d](/filings/0001326732-26-000015.md) | [56.9](/filings/0001326732-25-000053.md) | [61.5](/filings/0001326732-25-000075.md) | [58.2](/filings/0001326732-25-000087.md) | [51.1 d](/filings/0001326732-26-000015.md) | [58.6](/filings/0001326732-26-000043.md) | [61.7](/filings/0001326732-26-000056.md) | [54.4](/filings/0001326732-25-000087.md) | [64.8 d](/filings/0001326732-26-000015.md) | [64.7](/filings/0001326732-26-000043.md) | [71.9](/filings/0001326732-26-000056.md) |
| Operating income | $m | [(18.3)](/filings/0001326732-25-000021.md) | [(27.4) d](/filings/0001326732-26-000015.md) | [(54.7)](/filings/0001326732-25-000053.md) | [(55.4)](/filings/0001326732-25-000075.md) | [(55.2)](/filings/0001326732-25-000087.md) | [(13.2) d](/filings/0001326732-26-000015.md) | [(43.2)](/filings/0001326732-26-000043.md) | [(33.2)](/filings/0001326732-26-000056.md) | [(47.5)](/filings/0001326732-25-000087.md) | [(53.6) d](/filings/0001326732-26-000015.md) | [(77.9)](/filings/0001326732-26-000043.md) | [(37.1)](/filings/0001326732-26-000056.md) |
| Interest expense | $m | [0.0](/filings/0001326732-25-000021.md) | [6.2 d](/filings/0001326732-25-000015.md) | [9.7](/filings/0001326732-25-000017.md) | [9.3](/filings/0001326732-25-000075.md) | [9.0](/filings/0001326732-25-000087.md) | [8.7 d](/filings/0001326732-26-000015.md) | [8.7](/filings/0001326732-26-000043.md) | [8.2](/filings/0001326732-26-000056.md) | [7.7](/filings/0001326732-25-000087.md) | [7.4 d](/filings/0001326732-26-000015.md) | [4.7](/filings/0001326732-26-000043.md) | [7.4](/filings/0001326732-26-000056.md) |
| Income tax | $m | [0.0](/filings/0001326732-25-000021.md) | [13.7 d](/filings/0001326732-26-000015.md) | [0.0](/filings/0001326732-25-000053.md) | [0.0](/filings/0001326732-25-000075.md) | [0.0](/filings/0001326732-25-000087.md) | [1.6 d](/filings/0001326732-26-000015.md) | [0.4](/filings/0001326732-26-000043.md) | [(0.3)](/filings/0001326732-26-000056.md) | [0.0](/filings/0001326732-25-000087.md) | [2.4 d](/filings/0001326732-26-000015.md) | [0.3](/filings/0001326732-26-000043.md) | [(0.2)](/filings/0001326732-26-000056.md) |
| Net income | $m | [(24.3)](/filings/0001326732-25-000021.md) | [(26.1) d](/filings/0001326732-26-000015.md) | [(73.4)](/filings/0001326732-25-000053.md) | [(67.3)](/filings/0001326732-25-000075.md) | [(46.3)](/filings/0001326732-25-000087.md) | [(45.6) d](/filings/0001326732-26-000015.md) | [(48.4)](/filings/0001326732-26-000043.md) | [(30.8)](/filings/0001326732-26-000056.md) | [(6.0)](/filings/0001326732-25-000087.md) | [(6.7) d](/filings/0001326732-26-000015.md) | [(129)](/filings/0001326732-26-000043.md) | [(21.7)](/filings/0001326732-26-000056.md) |
| Diluted EPS | $ per share | [(0.40)](/filings/0001326732-25-000021.md) | not reported | [(1.20)](/filings/0001326732-25-000053.md) | [(1.09)](/filings/0001326732-25-000075.md) | [(0.72)](/filings/0001326732-25-000087.md) | not reported | [(0.66)](/filings/0001326732-26-000043.md) | [(0.41)](/filings/0001326732-26-000056.md) | [(0.08)](/filings/0001326732-25-000087.md) | not reported | [(1.71)](/filings/0001326732-26-000043.md) | [(0.29)](/filings/0001326732-26-000056.md) |
| Basic EPS | $ per share | [(0.40)](/filings/0001326732-25-000021.md) | not reported | [(1.20)](/filings/0001326732-25-000053.md) | [(1.09)](/filings/0001326732-25-000075.md) | [(0.72)](/filings/0001326732-25-000087.md) | not reported | [(0.66)](/filings/0001326732-26-000043.md) | [(0.41)](/filings/0001326732-26-000056.md) | [(0.08)](/filings/0001326732-25-000087.md) | not reported | [(1.71)](/filings/0001326732-26-000043.md) | [(0.29)](/filings/0001326732-26-000056.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating, us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [52.7](/filings/0001326732-25-000021.md) | [53.8](/filings/0001326732-25-000029.md) | [31.0](/filings/0001326732-25-000017.md) | [30.8](/filings/0001326732-25-000019.md) | [29.0](/filings/0001326732-25-000021.md) | [40.9](/filings/0001326732-26-000015.md) | [39.7](/filings/0001326732-25-000053.md) | [44.4](/filings/0001326732-25-000075.md) | [28.3](/filings/0001326732-25-000087.md) | [54.1](/filings/0001326732-26-000056.md) | [14.2](/filings/0001326732-26-000043.md) | [44.7](/filings/0001326732-26-000056.md) |
| Current assets | $m | [571](/filings/0001326732-23-000042.md) | [636](/filings/0001326732-25-000029.md) | [575](/filings/0001326732-25-000017.md) | [569](/filings/0001326732-25-000019.md) | [590](/filings/0001326732-25-000021.md) | [578](/filings/0001326732-26-000015.md) | [521](/filings/0001326732-25-000053.md) | [513](/filings/0001326732-25-000075.md) | [518](/filings/0001326732-25-000087.md) | [600](/filings/0001326732-26-000056.md) | [483](/filings/0001326732-26-000043.md) | [523](/filings/0001326732-26-000056.md) |
| Total assets | $m | [778](/filings/0001326732-23-000042.md) | [965](/filings/0001326732-25-000029.md) | [897](/filings/0001326732-25-000017.md) | [841](/filings/0001326732-25-000019.md) | [1,000](/filings/0001326732-25-000021.md) | [952](/filings/0001326732-26-000015.md) | [905](/filings/0001326732-25-000053.md) | [879](/filings/0001326732-25-000075.md) | [869](/filings/0001326732-25-000087.md) | [875](/filings/0001326732-26-000056.md) | [737](/filings/0001326732-26-000043.md) | [725](/filings/0001326732-26-000056.md) |
| Current liabilities | $m | [53.0](/filings/0001326732-23-000042.md) | [73.9](/filings/0001326732-25-000029.md) | [71.1](/filings/0001326732-25-000017.md) | [75.6](/filings/0001326732-25-000019.md) | [90.8](/filings/0001326732-25-000021.md) | [87.4](/filings/0001326732-26-000015.md) | [88.4](/filings/0001326732-25-000053.md) | [96.1](/filings/0001326732-25-000075.md) | [86.5](/filings/0001326732-25-000087.md) | [95.9](/filings/0001326732-26-000056.md) | [73.5](/filings/0001326732-26-000043.md) | [81.9](/filings/0001326732-26-000056.md) |
| Total liabilities | $m | [109](/filings/0001326732-23-000042.md) | [303](/filings/0001326732-25-000029.md) | [297](/filings/0001326732-25-000017.md) | [292](/filings/0001326732-25-000019.md) | [294](/filings/0001326732-25-000021.md) | [278](/filings/0001326732-26-000015.md) | [265](/filings/0001326732-25-000053.md) | [259](/filings/0001326732-25-000075.md) | [243](/filings/0001326732-25-000087.md) | [240](/filings/0001326732-26-000056.md) | [221](/filings/0001326732-26-000043.md) | [222](/filings/0001326732-26-000056.md) |
| Long-term debt | $m | not reported | [162](/filings/0001326732-25-000029.md) | [151](/filings/0001326732-25-000017.md) | [141](/filings/0001326732-25-000019.md) | [128](/filings/0001326732-25-000021.md) | [115](/filings/0001326732-26-000015.md) | [102](/filings/0001326732-25-000053.md) | [94.7](/filings/0001326732-25-000075.md) | [87.8](/filings/0001326732-25-000087.md) | [76.5](/filings/0001326732-26-000056.md) | [82.1](/filings/0001326732-26-000043.md) | [77.5](/filings/0001326732-26-000056.md) |
| Current portion of debt | $m | not reported | [27.7](/filings/0001326732-25-000029.md) | [34.2](/filings/0001326732-25-000017.md) | [38.9](/filings/0001326732-25-000019.md) | [44.5](/filings/0001326732-25-000021.md) | [48.4](/filings/0001326732-26-000015.md) | [52.5](/filings/0001326732-25-000053.md) | [50.3](/filings/0001326732-25-000075.md) | [45.4](/filings/0001326732-25-000087.md) | [43.3](/filings/0001326732-26-000056.md) | [26.4](/filings/0001326732-26-000043.md) | [27.4](/filings/0001326732-26-000056.md) |
| Shareholders' equity | $m | [669](/filings/0001326732-23-000042.md) | [662](/filings/0001326732-25-000029.md) | [600](/filings/0001326732-25-000017.md) | [550](/filings/0001326732-25-000019.md) | [709](/filings/0001326732-25-000021.md) | [678](/filings/0001326732-26-000015.md) | [640](/filings/0001326732-25-000053.md) | [620](/filings/0001326732-25-000075.md) | [625](/filings/0001326732-25-000087.md) | [636](/filings/0001326732-26-000056.md) | [516](/filings/0001326732-26-000043.md) | [503](/filings/0001326732-26-000056.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:DebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(27.3) d](/filings/0001326732-25-000021.md) | [18.2 d](/filings/0001326732-26-000015.md) | [(56.9)](/filings/0001326732-25-000053.md) | [(67.4) d](/filings/0001326732-25-000075.md) | [(28.1) d](/filings/0001326732-25-000087.md) | [(49.8) d](/filings/0001326732-26-000015.md) | [(16.2)](/filings/0001326732-26-000043.md) | [(36.4) d](/filings/0001326732-26-000056.md) | [(30.8) d](/filings/0001326732-25-000087.md) | [(51.7) d](/filings/0001326732-26-000015.md) | [(67.6)](/filings/0001326732-26-000043.md) | [(55.7) d](/filings/0001326732-26-000056.md) |
| Capital expenditure | $m | [2.8 d](/filings/0001326732-25-000021.md) | [1.0 d](/filings/0001326732-26-000015.md) | [0.1](/filings/0001326732-25-000053.md) | [3.0 d](/filings/0001326732-25-000075.md) | [1.3 d](/filings/0001326732-25-000087.md) | [1.7 d](/filings/0001326732-26-000015.md) | [1.4](/filings/0001326732-26-000043.md) | [0.4 d](/filings/0001326732-26-000056.md) | [0.2 d](/filings/0001326732-25-000087.md) | [1.1 d](/filings/0001326732-26-000015.md) | [0.6](/filings/0001326732-26-000043.md) | [0.5 d](/filings/0001326732-26-000056.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [59.7](/filings/0001326732-23-000042.md) | [59.8](/filings/0001326732-25-000017.md) | [59.8](/filings/0001326732-25-000019.md) | [60.6](/filings/0001326732-25-000021.md) | [61.2](/filings/0001326732-25-000053.md) | [61.7](/filings/0001326732-25-000075.md) | [64.0](/filings/0001326732-25-000087.md) | [73.7](/filings/0001326732-26-000043.md) | [74.3](/filings/0001326732-26-000056.md) | [74.4](/filings/0001326732-25-000087.md) | [75.2](/filings/0001326732-26-000043.md) | [75.9](/filings/0001326732-26-000056.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 74,353,397 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001326732-26-000056.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.